A novel in vitro metric predicts in vivo efficacy of inhaled silver-based antimicrobials in a murine Pseudomonas aeruginosa pneumonia model

Parth N. Shah, Kush N. Shah, Justin A. Smolen, Jasur A. Tagaev, Jose Torrealba, Lan Zhou, Shiyi Zhang, Fuwu Zhang, Patrick O. Wagers, Matthew J. Panzner, Wiley J. Youngs, Karen L. Wooley, Carolyn L. Cannon

Research output: Contribution to journalArticle

Abstract

To address the escalating problem of antimicrobial resistance and the dwindling antimicrobial pipeline, we have developed a library of novel aerosolizable silver-based antimicrobials, particularly for the treatment of pulmonary infections. To rapidly screen this library and identify promising candidates, we have devised a novel in vitro metric, named the "drug efficacy metric" (DEM), which integrates both the antibacterial activity and the on-target, host cell cytotoxicity. DEMs calculated using an on-target human bronchial epithelial cell-line correlates well (R2 > 0.99) with in vivo efficacy, as measured by median survival hours in a Pseudomonas aeruginosa pneumonia mouse model following aerosolized antimicrobial treatment. In contrast, DEMs derived using off-target primary human dermal fibroblasts correlate poorly (R2 = 0.0595), which confirms our hypothesis. SCC1 and SCC22 have been identified as promising drug candidates through these studies, and SCC22 demonstrates a dose-dependent survival advantage compared to sham treatment. Finally, silver-bearing biodegradable nanoparticles were predicted to exhibit excellent in vivo efficacy based on its in vitro DEM value, which was confirmed in our mouse pneumonia model. Thus, the DEM successfully predicted the efficacy of various silver-based antimicrobials, and may serve as an excellent tool for the rapid screening of potential antimicrobial candidates without the need for extensive animal experimentation.

Original languageEnglish (US)
Article number6376
JournalScientific Reports
Volume8
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Silver
Pseudomonas aeruginosa
Pneumonia
Pharmaceutical Preparations
Libraries
Survival
Nanoparticles
Fibroblasts
Epithelial Cells
Placebos
Cell Line
Lung
Skin
In Vitro Techniques
Therapeutics
Infection

ASJC Scopus subject areas

  • General

Cite this

A novel in vitro metric predicts in vivo efficacy of inhaled silver-based antimicrobials in a murine Pseudomonas aeruginosa pneumonia model. / Shah, Parth N.; Shah, Kush N.; Smolen, Justin A.; Tagaev, Jasur A.; Torrealba, Jose; Zhou, Lan; Zhang, Shiyi; Zhang, Fuwu; Wagers, Patrick O.; Panzner, Matthew J.; Youngs, Wiley J.; Wooley, Karen L.; Cannon, Carolyn L.

In: Scientific Reports, Vol. 8, No. 1, 6376, 01.12.2018.

Research output: Contribution to journalArticle

Shah, PN, Shah, KN, Smolen, JA, Tagaev, JA, Torrealba, J, Zhou, L, Zhang, S, Zhang, F, Wagers, PO, Panzner, MJ, Youngs, WJ, Wooley, KL & Cannon, CL 2018, 'A novel in vitro metric predicts in vivo efficacy of inhaled silver-based antimicrobials in a murine Pseudomonas aeruginosa pneumonia model', Scientific Reports, vol. 8, no. 1, 6376. https://doi.org/10.1038/s41598-018-24200-w
Shah, Parth N. ; Shah, Kush N. ; Smolen, Justin A. ; Tagaev, Jasur A. ; Torrealba, Jose ; Zhou, Lan ; Zhang, Shiyi ; Zhang, Fuwu ; Wagers, Patrick O. ; Panzner, Matthew J. ; Youngs, Wiley J. ; Wooley, Karen L. ; Cannon, Carolyn L. / A novel in vitro metric predicts in vivo efficacy of inhaled silver-based antimicrobials in a murine Pseudomonas aeruginosa pneumonia model. In: Scientific Reports. 2018 ; Vol. 8, No. 1.
@article{356ff9149d9b4903aa8afde17412af62,
title = "A novel in vitro metric predicts in vivo efficacy of inhaled silver-based antimicrobials in a murine Pseudomonas aeruginosa pneumonia model",
abstract = "To address the escalating problem of antimicrobial resistance and the dwindling antimicrobial pipeline, we have developed a library of novel aerosolizable silver-based antimicrobials, particularly for the treatment of pulmonary infections. To rapidly screen this library and identify promising candidates, we have devised a novel in vitro metric, named the {"}drug efficacy metric{"} (DEM), which integrates both the antibacterial activity and the on-target, host cell cytotoxicity. DEMs calculated using an on-target human bronchial epithelial cell-line correlates well (R2 > 0.99) with in vivo efficacy, as measured by median survival hours in a Pseudomonas aeruginosa pneumonia mouse model following aerosolized antimicrobial treatment. In contrast, DEMs derived using off-target primary human dermal fibroblasts correlate poorly (R2 = 0.0595), which confirms our hypothesis. SCC1 and SCC22 have been identified as promising drug candidates through these studies, and SCC22 demonstrates a dose-dependent survival advantage compared to sham treatment. Finally, silver-bearing biodegradable nanoparticles were predicted to exhibit excellent in vivo efficacy based on its in vitro DEM value, which was confirmed in our mouse pneumonia model. Thus, the DEM successfully predicted the efficacy of various silver-based antimicrobials, and may serve as an excellent tool for the rapid screening of potential antimicrobial candidates without the need for extensive animal experimentation.",
author = "Shah, {Parth N.} and Shah, {Kush N.} and Smolen, {Justin A.} and Tagaev, {Jasur A.} and Jose Torrealba and Lan Zhou and Shiyi Zhang and Fuwu Zhang and Wagers, {Patrick O.} and Panzner, {Matthew J.} and Youngs, {Wiley J.} and Wooley, {Karen L.} and Cannon, {Carolyn L.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-24200-w",
language = "English (US)",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - A novel in vitro metric predicts in vivo efficacy of inhaled silver-based antimicrobials in a murine Pseudomonas aeruginosa pneumonia model

AU - Shah, Parth N.

AU - Shah, Kush N.

AU - Smolen, Justin A.

AU - Tagaev, Jasur A.

AU - Torrealba, Jose

AU - Zhou, Lan

AU - Zhang, Shiyi

AU - Zhang, Fuwu

AU - Wagers, Patrick O.

AU - Panzner, Matthew J.

AU - Youngs, Wiley J.

AU - Wooley, Karen L.

AU - Cannon, Carolyn L.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - To address the escalating problem of antimicrobial resistance and the dwindling antimicrobial pipeline, we have developed a library of novel aerosolizable silver-based antimicrobials, particularly for the treatment of pulmonary infections. To rapidly screen this library and identify promising candidates, we have devised a novel in vitro metric, named the "drug efficacy metric" (DEM), which integrates both the antibacterial activity and the on-target, host cell cytotoxicity. DEMs calculated using an on-target human bronchial epithelial cell-line correlates well (R2 > 0.99) with in vivo efficacy, as measured by median survival hours in a Pseudomonas aeruginosa pneumonia mouse model following aerosolized antimicrobial treatment. In contrast, DEMs derived using off-target primary human dermal fibroblasts correlate poorly (R2 = 0.0595), which confirms our hypothesis. SCC1 and SCC22 have been identified as promising drug candidates through these studies, and SCC22 demonstrates a dose-dependent survival advantage compared to sham treatment. Finally, silver-bearing biodegradable nanoparticles were predicted to exhibit excellent in vivo efficacy based on its in vitro DEM value, which was confirmed in our mouse pneumonia model. Thus, the DEM successfully predicted the efficacy of various silver-based antimicrobials, and may serve as an excellent tool for the rapid screening of potential antimicrobial candidates without the need for extensive animal experimentation.

AB - To address the escalating problem of antimicrobial resistance and the dwindling antimicrobial pipeline, we have developed a library of novel aerosolizable silver-based antimicrobials, particularly for the treatment of pulmonary infections. To rapidly screen this library and identify promising candidates, we have devised a novel in vitro metric, named the "drug efficacy metric" (DEM), which integrates both the antibacterial activity and the on-target, host cell cytotoxicity. DEMs calculated using an on-target human bronchial epithelial cell-line correlates well (R2 > 0.99) with in vivo efficacy, as measured by median survival hours in a Pseudomonas aeruginosa pneumonia mouse model following aerosolized antimicrobial treatment. In contrast, DEMs derived using off-target primary human dermal fibroblasts correlate poorly (R2 = 0.0595), which confirms our hypothesis. SCC1 and SCC22 have been identified as promising drug candidates through these studies, and SCC22 demonstrates a dose-dependent survival advantage compared to sham treatment. Finally, silver-bearing biodegradable nanoparticles were predicted to exhibit excellent in vivo efficacy based on its in vitro DEM value, which was confirmed in our mouse pneumonia model. Thus, the DEM successfully predicted the efficacy of various silver-based antimicrobials, and may serve as an excellent tool for the rapid screening of potential antimicrobial candidates without the need for extensive animal experimentation.

UR - http://www.scopus.com/inward/record.url?scp=85045947840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045947840&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-24200-w

DO - 10.1038/s41598-018-24200-w

M3 - Article

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 6376

ER -